155 related articles for article (PubMed ID: 34254287)
21. Perspectives and Future Directions for Acute Lymphoblastic Leukemia.
Advani AS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S6-9. PubMed ID: 27521327
[No Abstract] [Full Text] [Related]
22. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
23. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gore L; Locatelli F; Zugmaier G; Handgretinger R; O'Brien MM; Bader P; Bhojwani D; Schlegel PG; Tuglus CA; von Stackelberg A
Blood Cancer J; 2018 Aug; 8(9):80. PubMed ID: 30190453
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
25. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
[No Abstract] [Full Text] [Related]
26. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
27. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
[TBL] [Abstract][Full Text] [Related]
29. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
30. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Zhao Y; Aldoss I; Qu C; Crawford JC; Gu Z; Allen EK; Zamora AE; Alexander TB; Wang J; Goto H; Imamura T; Akahane K; Marcucci G; Stein AS; Bhatia R; Thomas PG; Forman SJ; Mullighan CG; Roberts KG
Blood; 2021 Jan; 137(4):471-484. PubMed ID: 32881995
[TBL] [Abstract][Full Text] [Related]
31. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
Rayes A; McMasters RL; O'Brien MM
Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
[TBL] [Abstract][Full Text] [Related]
32. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.
Mejstríková E; Hrusak O; Borowitz MJ; Whitlock JA; Brethon B; Trippett TM; Zugmaier G; Gore L; von Stackelberg A; Locatelli F
Blood Cancer J; 2017 Dec; 7(12):659. PubMed ID: 29259173
[No Abstract] [Full Text] [Related]
33. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
[TBL] [Abstract][Full Text] [Related]
34. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
[TBL] [Abstract][Full Text] [Related]
35. Infantile mixed phenotype acute leukemia (bilineal and biphenotypic) with t(10;11)(p12;q23);MLL-MLLT10.
Lou Z; Zhang CC; Tirado CA; Slone T; Zheng J; Zaremba CM; Oliver D; Chen W
Leuk Res; 2010 Aug; 34(8):1107-9. PubMed ID: 20299091
[TBL] [Abstract][Full Text] [Related]
36. A pediatric case of
Murphy L; Siegele B; Carstens B; Hartman L; Faulk K
Leuk Lymphoma; 2024 Jun; 65(6):843-847. PubMed ID: 38372299
[No Abstract] [Full Text] [Related]
37. Extramedullary relapse of
Aldoss I; Song JY
Blood; 2018 May; 131(22):2507. PubMed ID: 29853461
[No Abstract] [Full Text] [Related]
38. Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.
Advani AS
Clin Adv Hematol Oncol; 2011 Oct; 9(10):776-7. PubMed ID: 22252580
[No Abstract] [Full Text] [Related]
39. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
Gökbuget N; Dombret H; Giebel S; Brüggemann M; Doubek M; Foa R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Maria Ribera J; Schoonen M; Tuglus C; Zugmaier G; Bassan R
Eur J Haematol; 2020 Apr; 104(4):299-309. PubMed ID: 31876009
[TBL] [Abstract][Full Text] [Related]
40. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
